Vaccine News and Research

Latest Vaccine News and Research

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

Atox Bio Inc. today announced that it successfully completed the dosing of the first subject in its phase 1 clinical study of AB103, a novel therapy for the treatment of severe bacterial infections and sepsis.

15 Sep 2010

Arizona State University receives grant to protect warfighters from infectious diseases

Scientists at the Biodesign Institute at Arizona State University have received a 2-year, $5.3 million grant from the Defense Advanced Research Projects Agency (DARPA) to protect warfighters in the event of exposure to infectious diseases during deployment.

15 Sep 2010

CytoGenix reports positive results of CYDBA507 avian influenza vaccine candidate

CytoGenix reports positive results of an animal study where mice were immunized with CYDBA507, CytoGenix avian influenza vaccine candidate, protected against lethal challenge with avian influenza virus.

15 Sep 2010

Pepscan, Tibotec sign Research and License Agreement

Pepscan Therapeutics, the Netherlands based biotechnology firm focusing on protein mimicry technology for the generation of novel therapeutics, today announced that it has signed a Research and License Agreement with Tibotec Pharmaceuticals, Ireland. Under the agreement Pepscan using its CLIPS technology will work with Tibotec to develop novel therapeutic peptides against an undisclosed target.

14 Sep 2010

Parents struggle to balance emotional, rational aspects of immunization: Poll

Back-to-school is in full swing and parents are breathing a collective sigh of relief now that their kids are back in the classroom. But with the back-to-school rush comes the reminder that immunizations must be updated - and that thought has parents filled with anything but relief. In fact, according to a new poll of Ontarians, parents struggle emotionally with immunizing their children - and themselves - before making the decision to do so.

14 Sep 2010

Life Technologies finalizes cell line license agreement for recombinant protein production

Life Technologies Corporation today announced that it has finalized cell line license agreements with a number of companies to provide rights to Life Technologies' proprietary CHO (Chinese hamster ovary) cell lines for the production of recombinant proteins used as therapeutic agents and vaccines.

14 Sep 2010

Human cytomegalovirus cloned

A team of Welsh scientists have successfully cloned a human virus offering new hope for the treatment of potentially life-threatening diseases.

14 Sep 2010

Seattle Times examines how Gates Foundation's goal to eradicate malaria is affecting research

The Seattle Times examines how the Bill & Melinda Gates Foundation's goal to eradicate malaria is shaping aspects of global research.

14 Sep 2010

Sanofi Pasteur files Fluzone Intradermal influenza virus vaccine sBLA with FDA

Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today that it has filed a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for Fluzone® Intradermal (Influenza Virus Vaccine). The file has been accepted by the FDA and an action date is anticipated in the first half of 2011.

From BD (Becton, Dickinson and Company) 14 Sep 2010

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from the North Mississippi Health Services Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Sep 2010

Geron, UCS collaborate to develop hESC-derived chondrocytes for cartilage damage, joint disease treatment

Geron Corporation today announced that the company has entered into a collaboration with University Campus Suffolk (UCS) in the U.K. to develop human embryonic stem cell-derived chondrocytes for the treatment of cartilage damage and joint disease.

13 Sep 2010

Geron signs worldwide, exclusive license agreement with University of Edinburgh

Geron Corporation today announced that it has entered into a worldwide, exclusive license agreement with the University of Edinburgh covering technology that allows the efficient production of chondrocytes (cartilage forming cells) from human pluripotent stem cells.

13 Sep 2010

Daiichi Sankyo receives marketing approval for Inavir in Japan

Biota Holdings Limited today announced that Daiichi Sankyo has received approval to manufacture and market Inavir® in Japan. Inavir® is Daiichi Sankyo's brand of laninamivir octanoate and also previously known as CS-8958. The approved indication is for the treatment of influenza in adults and children.

13 Sep 2010

New book relates mercury in vaccines to autism

The U.S. government revealed last week that they will compensate a family millions of dollars for their daughter's injury related to her infant vaccines that contained mercury and the subsequent development of autism. Yet, the CDC continues to tell the public that there is no connection between vaccines and autism and that the mercury has been removed, although the flu shot recommended for all pregnant women, infants, and children continues to be preserved with mercury.

13 Sep 2010

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Vical Incorporated announced today the achievement of key efficacy, immunogenicity and safety results in a Phase 2 trial, establishing its TransVax™ cytomegalovirus (CMV) vaccine as the first to provide evidence of protection in immunocompromised hematopoietic cell transplant (HCT) recipients, and defining a potential pathway for further development.

13 Sep 2010

Cell quality control mechanism research paves way for new understanding of neurodegenerative diseases

Scientists from The Scripps Research Institute have solved a long-standing mystery of how cells conduct "quality control" to eliminate the toxic effects of a certain kind of error in protein production. The findings may lead to a better understanding of a host of neurodegenerative diseases.

13 Sep 2010

Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study

Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that it has achieved best-in-class immune responses in its Phase I dose escalation study of VGX-3100, its DNA vaccine to treat pre-cancerous cervical dysplasias and cervical cancers caused by human papillomavirus (HPV) types 16 and 18.

13 Sep 2010

Researchers develop mathematical framework for vaccine stockpile implications

A creative version of a classic engineering technique may improve decisions about building and using supplies of important pediatric vaccines, potentially leading to lower public health costs and healthier children.The United States maintains a six-month supply of common pediatric vaccines to ensure protection from deadly diseases, such as the flu, polio, and diphtheria, despite interruptions in vaccine production.

13 Sep 2010

NanoBio Corporation to present Nanoemulsion Phase I clinical trial data at ICAAC Conference

NanoBio Corporation today announced it will present data from two separate Phase 1 clinical trials at the 2010 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), taking place in Boston, Mass. from Sept. 12-15.

13 Sep 2010

Advaxis publishes research article on Her2 antigen for Listeria vaccine

Scientists at Advaxis, Inc.,the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, recently had their research using ADXS31-164, a live Listeria vaccine that targets Her2, published in a leading peer reviewed journal (Shahabi, et al 2010 Cancer Gene Therapy epublished ahead of print).

13 Sep 2010

Vaccine News and Research

Latest Vaccine News and Research

Atox Bio doses first subject in AB103 Phase 1 study for severe bacterial infections and sepsis

Arizona State University receives grant to protect warfighters from infectious diseases

CytoGenix reports positive results of CYDBA507 avian influenza vaccine candidate

Pepscan, Tibotec sign Research and License Agreement

Parents struggle to balance emotional, rational aspects of immunization: Poll

Life Technologies finalizes cell line license agreement for recombinant protein production

Human cytomegalovirus cloned

Seattle Times examines how Gates Foundation's goal to eradicate malaria is affecting research

Sanofi Pasteur files Fluzone Intradermal influenza virus vaccine sBLA with FDA

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

Geron, UCS collaborate to develop hESC-derived chondrocytes for cartilage damage, joint disease treatment

Geron signs worldwide, exclusive license agreement with University of Edinburgh

Daiichi Sankyo receives marketing approval for Inavir in Japan

New book relates mercury in vaccines to autism

Vical's TransVax CMV vaccine achieves key endpoints in Phase 2 trial in immunocompromised HCT recipients

Cell quality control mechanism research paves way for new understanding of neurodegenerative diseases

Inovio Pharmaceuticals achieves promising results in VGX-3100 Phase I study

Researchers develop mathematical framework for vaccine stockpile implications

NanoBio Corporation to present Nanoemulsion Phase I clinical trial data at ICAAC Conference

Advaxis publishes research article on Her2 antigen for Listeria vaccine

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Vaccine News and Research

Latest Vaccine News and Research

Event guide: 3rd mRNA Process Development & Manufacturing Europe eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in